Altered influenza virus haemagglutinin (HA)-derived peptide is potent therapy for CIA by inducing Th1 to Th2 shift

Cellular and Molecular Immunology

Volumn 8, Issue 4, 2011, Pages 348-358

  Sun, Jian ^a   Jia, Yuan ^a   Li, Ru ^a   Guo, Jianping ^a   Sun, Xiaolin ^a   Liu, Yanying ^a   Li, Yingni ^a   Yao, Haihong ^a   Liu, Xia ^a   Zhao, Jing ^a   Li, Zhanguo ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

altered HA peptide; collagen induced arthritis; Th1 Th2

Indexed keywords

COLLAGEN TYPE 2; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INFLUENZA VIRUS HEMAGGLUTININ; INFLUENZA VIRUS HEMAGGLUTININ PEPTIDE[308-317]; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTHRITIS; ARTICLE; BONE EROSION; CARTILAGE DEGENERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLUORESCENCE ACTIVATED CELL SORTING; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY INFILTRATE; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PANNUS; SPLEEN CELL; SYNOVIOCYTE; TH1 CELL; TH2 CELL; UPREGULATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; COLLAGEN TYPE II; CYTOKINES; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-4; MALE; MICE; MICE, INBRED DBA; ORTHOMYXOVIRIDAE; PEPTIDE FRAGMENTS; TH1 CELLS; TH2 CELLS;

MUS; ORTHOMYXOVIRIDAE;

EID: 79960054633     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2011.5     Document Type: Article

References (38)

1. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006; 6: 394-403.
2. Monach PA, Benoist C, Mathis D. The role of antibodies in mouse models of rheumatoid arthritis, and relevance to human disease. Adv Immunol 2004; 82: 217-248. (Pubitemid 38209512)
3. VanderBorght A, Geusens P, Raus J, Stinissen P. The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies. Semin Arthritis Rheum 2001; 31: 160-175. (Pubitemid 33140642)
4. Sekine T, Kato T, Masuko-Hongo K, Nakamura H, Yoshino S, Nishioka K et al. Type II collagen is a target antigen of clonally expanded T cell in the synovium of patients with rheumatoid arthritis. Ann Rheum Dis 1999; 58: 446-450. (Pubitemid 29317957)
5. Diab BY, Lambert NC, LFaqihi FE, Loubet-Lescoulié P, dePréval C, Coppin H. Human collagen II peptide 256-271 preferentially binds to HLA-DR molecules associated with susceptibility to rheumatoid arthritis. Immunogenetics 1999; 49: 36-44. (Pubitemid 29039264)
6. Dessen A, Lawrence CM, Cupo S, Zaller DM, Wiley DC. X-ray crystal structure of HLADR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 1997; 7: 473-481. (Pubitemid 27508699)
7. Dayan M, Sthoeger Z, Neiman A, Abarbanel J, Sela M, Mozes E. Immunomodulation by a dual altered peptide ligand of autoreactive responses to the acetylcholine receptor of peripheral blood lymphocytes of patients with myasthenia gravis. Hum Immunol 2004; 65: 571-577. (Pubitemid 38813408)
8. Kim HJ, Antel JP, Duquette P, Alleva DG, Conlon PJ, Bar-Or A. Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand. Clin Immunol 2002; 104: 105-114. (Pubitemid 35026220)
9. Hartemann-Heurtier A, Mars LT, Bercovici N, Desbois S, Cambouris C, Piaggio E et al. An altered self-peptide with superagonist activity blocks a CD8-mediated mouse model of type 1 diabetes. J Immunol 2004; 172: 915-922. (Pubitemid 38113749)
10. Santambrogio L, Lees MB, Sobel RA. Altered peptide ligand modulation of experimental allergic encephalomyelitis: immune responses within the CNS. J Neuroimmunol 1998; 81: 1-13. (Pubitemid 28248178)
11. Crowe PD, Qin Y, Conlon PJ, Antel JP. NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients. Ann Neurol 2000; 48: 758-765.
12. Xia L, Ru L, Zhanguo L. Altered influenza virus haemagglutinin peptides inhibit T cell responses to type II collagen in rheumatoid arthritis. Ann Rheum Dis 2005; 64: 1790-1791. (Pubitemid 41667160)
13. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002; 2: 933-944. (Pubitemid 37323214)
14. Mauri C, Williams RO, Walmsley M, Feldmann M. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol 1996; 26: 1511-1518. (Pubitemid 26229996)
15. Doncarli A, Stasiuk LM, Fournier C, Abehsira-Amar O. Conversion in vivo from an early dominant Th0/Th1 response to a Th2 phenotype during the development of collageninduced arthritis. Eur J Immunol 1997; 27: 1451-1458. (Pubitemid 27254838)
16. Smolen JS, Tohidast-Akrad M, Gal A, Kunaver M, Eberl G, Zenz P et al. The role of T-lymphocytes and cytokines in rheumatoid arthritis. Scand J Rheumatol 1996; 25: 1-4. (Pubitemid 26064964)
17. Joosten LA, Lubberts E, Durez P, Helsen MM, Jacobs MJ, Goldman M et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997; 40: 249-260. (Pubitemid 27114088)
18. Walmsley M, Katsikis PD, Abney E, Parry S, Williams RO, Maini RN et al. Interleukin-inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 1996; 39: 495-503.
19. Horsfall AC, Butler DM, Marinoval L, Warden PJ, Williams RO, Maini RN et al. Suppression of collagen-induced arthritis by continuous administration of interleukin-4. J Immunol 1997; 159: 5687-5696. (Pubitemid 127470100)
20. Watson WC, Townes AS. Genetic susceptibility to murine collagen II autoimmune arthritis. Proposed relationship to the IgG2 autoantibody subclass response, complement C5, major histocompatibility complex (MHC) and non-MHC loci. J Exp Med 1985; 162: 1878-1891. (Pubitemid 16149683)
21. OGarra A, Robinson D. Development and function of T helper 1 cells. Adv Immunol 2004; 83: 133-162. (Pubitemid 38657639)
22. Kim WU, Lee WK, Ryoo JW, Kim SH, Kim J, Youn J et al. Suppression of collageninduced arthritis by single administration of poly (lactic-co-glycolic acid) nanoparticles entrapping type II collagen: a novel treatment strategy for induction of oral tolerance. Arthritis Rheum 2002; 46: 1109-1120. (Pubitemid 34303826)
23. Nishikawa M, Myoui A, Tomita T, Takahi K, Nampei A, Yoshikawa H. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogenactivated protein kinase inhibitor FR167653. Arthritis Rheum 2003; 48: 2670-2681. (Pubitemid 37129445)
24. Houssiau FA, Devogelaer JP, van Damme J, de Deuxchaisnes CN, van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988; 31: 784-788.
25. Tremoulet AH, Albani S. Novel therapies for rheumatoid arthritis. Expert Opin Investig Drugs 2006; 15: 1427-1441. (Pubitemid 44615290)
26. Koch AE. Chemokines and their receptors in rheumatoid arthritis: future targets? Arthritis Rheum 2005; 52: 710-721. (Pubitemid 40365092)
27. Milani M, Ostlie N,WuH, Wang W, Conti-Fine BM. CD41 T andBcells cooperate in the immunoregulation of Experimental Autoimmune Myasthenia Gravis. J Neuroimmunol 2006; 179: 152-162. (Pubitemid 44441600)
28. Berner B, Akca D, Jung T, Muller GA, Reuss-Borst MA. Analysis of Th1 and Th2 cytokines expressing CD41 and CD81 T cells in rheumatoid arthritis by flow cytometry. J Rheumatol 2000; 27: 1128-1135. (Pubitemid 30262494)
29. Cremer MA, Rosloniec EF, Kang AH. The cartilage collagens: a review of their structure, organization, and role in the pathogenesis of experimental arthritis in animals and in human rheumatic disease. J Mol Med 1998; 76: 275-288. (Pubitemid 28098713)
30. Kim WU, Yoo WH, Park W, Kang YM, Kim SI, Park JH et al. IgG antibodies to type II collagen reflect inflammatory activity in patients with rheumatoid arthritis. J Rheumatol 2000; 27: 575-581. (Pubitemid 30151330)
31. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145-173. (Pubitemid 19138011)
32. Mukherjee P, Wu B, Mayton L, Kim SH, Robbins PD, Wooley PH. TNF receptor gene therapy results in suppression of IgG2a anticollagen antibody in collagen induced arthritis. Ann Rheum Dis 2003; 62: 707-714. (Pubitemid 36886403)
33. Myers LK, Stuart JM, Seyer JM, Kang AH. Identification of an immunosuppressive epitope of type II collagen that confers protection against collagen-induced arthritis. J Exp Med 1989; 170: 1999-2010. (Pubitemid 20010080)
34. Cher DJ, Mosmann TR. Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones. J Immunol 1987; 138: 3688-3694. (Pubitemid 17078235)
35. Nandakumar KS, Andrén M, Martinsson P, Bajtner E, Hellstrom S, Holmdahl R et al. Induction of arthritis by single monoclonal IgG anti-collagen type II antibodies and enhancement of arthritis in mice lacking inhibitory FcgammaRIIB. Eur J Immunol 2003; 33: 2269-2277. (Pubitemid 37010045)
36. Lu LF, Lind EF, Gondek DC, Bennett KA, Gleeson MW, Pino-Lagos K et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006; 442: 997-1002. (Pubitemid 44330250)
37. Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 2006; 310: 850-855. (Pubitemid 41567343)
38. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M et al. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 2006; 441: 235-238.